Search research articles
Contact Us
Filters
Showing results (91-100 of 141) with videos related to
Page
of 15
Sort By:
European Urology
|
February 13, 2018
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study
Joaquin Mateo, Heather H Cheng, Himisha Beltran, et al.
European Urology Oncology
|
February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
Ruben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
JAMA Oncology
|
July 25, 2024
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review
Heather H Cheng, Jeffrey W Shevach, Elena Castro, et al.
The Prostate
|
April 1, 2021
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer
Elisa M Ledet, Earle F Burgess, Alexandra O Sokolova, et al.
European Urology Oncology
|
March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Mamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
The Prostate
|
November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer
Christopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
JCO Precision Oncology
|
February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
Maria I Carlo, Veda N Giri, Channing J Paller, et al.
Nature Medicine
|
October 7, 2025
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Gerhardt Attard, Neeraj Agarwal, Julie N Graff, et al.
JCO Precision Oncology
|
March 7, 2024
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Stacy Loeb, Scott W Keith, Heather H Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Young K Chae, Fangxin Hong, Christos Vaklavas, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 141) with videos related to
Sort By:
Page
of 15
European Urology
|
February 13, 2018
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study
Joaquin Mateo, Heather H Cheng, Himisha Beltran, et al.
European Urology Oncology
|
February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
Ruben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
JAMA Oncology
|
July 25, 2024
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review
Heather H Cheng, Jeffrey W Shevach, Elena Castro, et al.
The Prostate
|
April 1, 2021
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer
Elisa M Ledet, Earle F Burgess, Alexandra O Sokolova, et al.
European Urology Oncology
|
March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Mamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
The Prostate
|
November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer
Christopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
JCO Precision Oncology
|
February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
Maria I Carlo, Veda N Giri, Channing J Paller, et al.
Nature Medicine
|
October 7, 2025
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Gerhardt Attard, Neeraj Agarwal, Julie N Graff, et al.
JCO Precision Oncology
|
March 7, 2024
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Stacy Loeb, Scott W Keith, Heather H Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Young K Chae, Fangxin Hong, Christos Vaklavas, et al.
Page
of 15